Julián Torre‐Cisneros

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 732 citations

Antimicrobial Susceptibility, Health Sciences, Carbapenem-resistant Gram-negative Bacteria +11

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

John R. Perfect, Kieren A. Marr, Thomas J. Walsh et al. · Clinical Infectious Diseases · 2003 · 674 citations · Full text

Anti-infective Agents, Antifungal Agent, Health Sciences +13

HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†

Juan A. Pineda, Manuel Romero‐Gómez, F. Díaz-García et al. · Hepatology · 2005 · 279 citations · Full text

Tuberculosis in Solid‐Organ Transplant Recipients: Consensus Statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology

José María Aguado, Julián Torre‐Cisneros, Jesús Fortün et al. · Clinical Infectious Diseases · 2009 · 255 citations

Drug Interactions, Pulmonary Tuberculosis, Transplantation +15

Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms

Elizabeth Temkin, Julián Torre‐Cisneros, Bojana Beovič et al. · Antimicrobial Agents and Chemotherapy · 2016 · 250 citations · Full text